News

From left, Himanshu Arora, Ph.D., with Ranjith Ramasamy, M.D.

Sylvester Researchers Show Nitric Oxide Suppresses Drug-Resistant Prostate Cancer

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown in animal models that S-nitrosoglutathione (GSNO), a compound that increases nitric oxide (NO) levels, suppresses castration-resistant prostate cancer and has a major impact on tumor microenvironments. The discovery could lead to new therapies for prostate cancer patients with few options.

Read more on the Miller School website »

From left, Ivonne Schulman, M.D., with Lina Shehadeh, Ph.D.

Miller School Researcher Receives $1.5 Million Grant to Study Role of Osteopontin in Heart Failure

A Miller School of Medicine researcher has received a $1.5 million grant from the National Heart, Lung and Blood Institute to study a potential new strategy for treating an intractable form of heart failure. “Prior studies have shown that lowering the level of a protein called osteopontin can ameliorate heart failure with reduced ejection fraction,” said Lina Shehadeh, Ph.D., assistant professor of medicine.

Read more on the Miller School website »

Stromal cells in the laboratory.

Mesenchymal Stromal Cells Shown to Prevent Lung and Skin Fibrosis, Restore Wound Healing

A cross-disciplinary group of researchers at the University of Miami Miller School of Medicine has found that allogeneic adipose-derived mesenchymal stromal cells (ASCs) will prevent lung and skin fibrosis, and restore wound healing.

Read more on the Miller School website »

51st Miami Winter Symposium Opens January 28

Stem Cells: Today’s Research Tomorrow’s Therapies will be the focus of the 51st Miami Winter Symposium, which will take place January 28-31 at the downtown Hyatt Regency Hotel January 28-31.

Read more on the Miller School website »

Six-minute walk test results improved with stem cell therapy.

Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty

Buoyed by promising results of a Phase I study demonstrating the safety of mesenchymal stem cell therapy to treat frailty in older adults, researchers at the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have taken it a step further. Now Phase II randomized, placebo-controlled trial findings have verified their initial study.

Read more on the Miller School website »

News Archives »